Halozyme Appoints David Ramsay as President Drug Delivery

Halozyme (Nasdaq: HALO) appointed David Ramsay as President Drug Delivery, effective June 30, 2026.

(Neutral)

(Positive)

Rhea-AI Summary

Halozyme (Nasdaq: HALO) appointed David Ramsay as President Drug Delivery, effective June 30, 2026. This is a newly created, enterprise-wide role.

Ramsay will drive growth of Halozyme's drug delivery technologies, set strategic priorities, and lead business development and alliance management, reporting to CEO Helen Torley.

Argus Jul 1 session

-1.61% close to close Open Argus

Details

News Market Reaction – HALO

On Jul 1, the first trading day after this news, HALO closed 1.61% below the previous close.

Data tracked by StockTitan Argus for the Jul 1 session.

Market Context

This announcement adds a seasoned leader with more than 30 years experience focused on drug delivery...

Analysis

This announcement adds a seasoned leader with more than 30 years experience focused on drug delivery growth. Recent Halozyme news has mostly been well‑received; key risks remain execution on partnerships and how governance and insider activity are perceived.

Key Figures

Effective date: June 30, 2026 Leadership experience: more than 30 years Interim CFO tenure: March 23 to June 8, 2026 +4 more

Effective date: June 30, 2026; Start date for David Ramsay as President Drug Delivery
Leadership experience: more than 30 years; Strategic financial leadership across biotechnology and life sciences sectors
Interim CFO tenure: March 23 to June 8, 2026; Period David Ramsay served as Interim Chief Financial Officer at Halozyme
CFO term: 2003 to 2009; First period David Ramsay served as Halozyme Chief Financial Officer
VP Corporate Development term: 2009 to 2013; Period serving as Vice President of Corporate Development at Halozyme
Second CFO term: 2013 to 2015; Second period David Ramsay served as Halozyme Chief Financial Officer
Bonti sale date: October 2018; Sale of Bonti, Inc. to Allergan plc where Ramsay was CFO

Historical Context

5 past events · Latest: Jun 15

5 events

Jun 15
Policy impact update

24h Move

+2.6%

Projected minimal Medicare pricing impact on royalty revenue and partnerships.
May 11
Earnings and buyback

24h Move

+6.8%

Strong Q1 2026 results plus new $1B repurchase and reiterated guidance.
May 07
GSK collaboration deal

24h Move

-1.8%

Global ENHANZE license with GSK for multiple oncology targets including ADCs.
May 06
Oruka partnership

24h Move

+0.7%

Hypercon tech license for ORKA-001 and option for one extra target.
Apr 30
Earnings call notice

24h Move

+0.5%

Announcement of Q1 2026 earnings release date and conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biologics, capital markets, corporate finance, royalty streams

4 terms

biologics medical

"untapped potential to dramatically improve the delivery of biologics for millions"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

capital markets financial

"including extensive experience in capital markets, corporate finance, investor relations"

Capital markets are places where people and organizations buy and sell long-term investments like stocks and bonds. They help connect those who need money to grow or fund projects with investors looking to earn returns over time. For investors, capital markets are important because they offer opportunities to invest, save, and grow their wealth through a variety of financial assets.

corporate finance financial

"including extensive experience in capital markets, corporate finance, investor relations"

Corporate finance is the set of decisions a company makes about getting and using money—how it raises funds, where it spends them, and how it manages cash and risk. For investors, these choices determine a company’s ability to grow, pay dividends or buy back shares, and survive downturns; think of it as a household’s budgeting and borrowing plan that signals whether the business is living within its means and planning for the future.

View in glossary

royalty streams financial

"resulting in new durable and growing royalty streams. I look forward to working"

Payments received over time based on sales, production, or use of an asset—such as a patent, song, drug, or mine—where the owner keeps a percentage of revenue rather than selling the asset outright. Investors care because royalty streams can provide steady, predictable income similar to receiving regular rent checks, can be bought or sold separately, and their value depends on how well the underlying product or resource performs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/30/2026 - 04:02 PM

SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026.

In this newly created role, Mr. Ramsay will have an enterprise-wide, cross-technology mandate, and will be responsible for driving the growth of Halozyme's drug delivery technologies by establishing clear strategic priorities and assuring best in class business development and alliance management. David will report to Helen Torley, President and Chief Executive Officer.

"I am delighted to have a business leader of David's experience assume this new position at a time of unprecedented opportunity and growth for Halozyme. In his recent role as Interim Chief Financial Officer, he demonstrated his deep experience and an expansive skillset including strategic assessment, industry and partner knowledge, and, of course, deep financial expertise," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I look forward to having David assume this newly established leadership role and contribute to the acceleration of value creation for our shareholders."

Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up.

David served as Interim Chief Financial Officer of Halozyme from March 23 to June 8, 2026, until the appointment of Darren Snellgrove as Chief Financial Officer, and was responsible for leading all financial operations for the Company.

He previously served as Halozyme's Chief Financial Officer from 2003 to 2009, Vice President of Corporate Development from 2009-2013 and again as Chief Financial Officer from 2013 to 2015, during which time the company evolved from a private enterprise to a billion‑dollar public biopharmaceutical company. During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018.

"I am thrilled to assume this new role at Halozyme at such an important time in the Company's evolution," said Mr. Ramsay. "Halozyme's broad technology portfolio has tremendous yet untapped potential to dramatically improve the delivery of biologics for millions more patients, collaborating with industry-leading biopharmaceutical partners and resulting in new durable and growing royalty streams. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders."

Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley, and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience and GSK.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE^® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx,Vertex Pharmaceuticals, and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^®and XYOSTED^®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including but not limited to unexpected levels of revenues and expenses, Halozyme's future growth (including the number of future patients using Halozyme's drug delivery technology) and shareholder value. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-david-ramsay-as-president-drug-delivery-302815025.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Halozyme (NASDAQ: HALO) announce on June 30, 2026 about David Ramsay?

Halozyme appointed David Ramsay as President Drug Delivery effective June 30, 2026. According to Halozyme, this new enterprise-wide role focuses on growing its drug delivery technologies and strengthening strategic priorities across business development and alliance management.

What are the responsibilities of Halozyme's new President Drug Delivery role (HALO)?

The President Drug Delivery will drive growth of Halozyme's drug delivery technologies and set strategic priorities. According to Halozyme, David Ramsay will also oversee business development and alliance management across technologies, reporting directly to President and Chief Executive Officer Helen Torley.

What is David Ramsay's background before becoming President Drug Delivery at Halozyme (HALO)?

David Ramsay has over 30 years of strategic financial leadership in biotechnology and life sciences. According to Halozyme, he previously served multiple terms as its Chief Financial Officer and Vice President of Corporate Development and held senior roles at Bonti prior to its sale to Allergan.

How recently did David Ramsay serve as Interim CFO at Halozyme (NASDAQ: HALO)?

David Ramsay served as Interim Chief Financial Officer of Halozyme from March 23 to June 8, 2026. According to Halozyme, he led all financial operations during this period, before Darren Snellgrove was appointed as Chief Financial Officer.

How has David Ramsay contributed to Halozyme's growth in earlier roles (HALO)?

In earlier CFO and corporate development roles, David Ramsay guided Halozyme through significant growth. According to Halozyme, he helped the company evolve from a private enterprise to a billion-dollar public biopharmaceutical company and built foundational financial and commercialization infrastructure.

What is David Ramsay's view on Halozyme's drug delivery technology potential (HALO)?

David Ramsay believes Halozyme's technology portfolio has significant untapped potential to improve biologics delivery. According to Halozyme, he expects collaborations with industry-leading partners to support new royalty streams and aims to drive sustainable growth and value creation for shareholders in his new role.

Halozyme Appoints David Ramsay as President Drug Delivery

Rhea-AI Summary

Positive